ADRA2A Antibody

What is ADRA2A and what is its role in the nervous system?

ADRA2A (Alpha-2A Adrenergic Receptor) is a member of the G protein-coupled receptor superfamily that plays a critical role in regulating neurotransmitter release from sympathetic nerves and adrenergic neurons in the central nervous system. Studies in mice have demonstrated that the α2A subtype specifically inhibits neurotransmitter release at high stimulation frequencies, while the α2C subtype modulates neurotransmission at lower levels of nerve activity . ADRA2A mediates catecholamine-induced inhibition of adenylate cyclase through G protein actions and is involved in cytoskeleton organization . The gene encoding human ADRA2A is mapped to chromosome 10q25.2 and contains no introns in either coding or untranslated sequences .

What are the molecular characteristics of the ADRA2A protein?

The significant difference between calculated and observed molecular weights is likely due to post-translational modifications, particularly glycosylation . This discrepancy is important to consider when interpreting Western blot results.

What applications are ADRA2A antibodies commonly used for?

ADRA2A antibodies are validated for multiple research applications with varying optimization requirements:

Boster validates their antibodies on WB, IHC, ICC, Immunofluorescence, and ELISA with known positive and negative samples to ensure specificity and high affinity . Researchers should perform their own validation when applying these antibodies to new experimental systems.

How does ADRA2A contribute to Alzheimer's disease pathology?

Recent research has uncovered a significant role for ADRA2A in Alzheimer's disease (AD) pathogenesis. Studies using genetic approaches demonstrated that ADRA2A deficiency substantially reduces AD-associated neuropathology:

• In APP/PS1,Adra2a−/− mice, both Aβ40 and Aβ42 peptide levels were significantly reduced in the cerebrum compared to APP/PS1,Adra2a+/+ controls

• Cerebral Aβ deposits were markedly decreased in APP/PS1,Adra2a−/− mice at 6 months of age

• Neuroinflammation markers, including activated microglia and astrocytes, were significantly reduced in ADRA2A-deficient AD model mice

These findings provide compelling evidence that endogenous α2AAR activity enhances brain amyloidosis in AD models, suggesting ADRA2A modulates APP endocytic sorting mechanisms that influence amyloid pathology . This represents the first evidence that a G protein-coupled receptor directly contributes to amyloidogenesis in AD.

How effective are pharmacological interventions targeting ADRA2A in disease models?

Pharmacological blockade of ADRA2A has shown promising results in Alzheimer's disease models:

• Treatment with idazoxan (a selective α2AR antagonist) in APP/PS1 mice starting at 10 weeks of age (before Aβ deposition) resulted in:

  • Dramatic reduction in human Aβ peptides, especially Aβ42, in the cerebrum

  • Significant decrease in Aβ deposition in both hippocampus and cortex

  • Reduced endogenous Aβ40 and Aβ42 levels even in non-transgenic mice

These results demonstrate that α2AR antagonist treatment effectively reduces Aβ generation and AD-related pathology when administered at early disease stages . The study protocol involved:

• Treatment initiation at 10 weeks of age

• Administration for 10 weeks

• One-week drug washout period

• Behavioral testing for 2 weeks

• Pathological analysis

This methodological approach provides a framework for researchers investigating similar pharmacological interventions in neurodegenerative disease models.

How is ADRA2A expression regulated epigenetically in neuropsychiatric disorders?

ADRA2A expression is regulated through complex epigenetic mechanisms, particularly in neuropsychiatric disorders like schizophrenia:

• mRNA expression is selectively upregulated in antipsychotic-treated schizophrenia subjects (+93%)

• The ADRA2A promoter region shows significant epigenetic modification through histone methylation and acetylation in human dorsolateral prefrontal cortex (DLPFC)

• "Bivalent chromatin" at the ADRA2A promoter in schizophrenia is characterized by:

  • Increased permissive H3K4me3 modifications

  • Increased repressive H3K27me3 modifications

• Enhanced H4K16ac at the ADRA2A promoter may trigger upregulation of gene expression

These findings suggest that epigenetic predisposition differentially modulates ADRA2A expression in schizophrenia, potentially influenced by antipsychotic treatment. Researchers investigating these mechanisms should employ chromatin immunoprecipitation (ChIP) techniques to evaluate histone modifications at the ADRA2A promoter.

What methodological considerations are critical for optimizing Western blot detection of ADRA2A?

Western blot detection of ADRA2A requires careful optimization due to several unique characteristics of this protein:

• Molecular Weight Discrepancy: While the calculated molecular weight is approximately 49 kDa, the observed molecular weight is typically around 150 kDa due to post-translational modifications, particularly glycosylation .

• Antibody Selection: Use validated antibodies with confirmed specificity for ADRA2A. The recommended working dilution for Western blot is 0.1-0.5 μg/ml .

• Sample Preparation Protocol:

  • Include protease inhibitors to prevent degradation

  • Consider membrane fraction enrichment for improved detection

  • Maintain appropriate sample buffer conditions to preserve epitope integrity

• Positive Controls: HELA and PANC cell lysates have been validated as positive controls for ADRA2A detection .

• Cross-Reactivity Testing: Verify absence of cross-reactivity with other alpha-2 adrenergic receptor subtypes (ADRA2B, ADRA2C).

Researchers should be aware that glycosylation patterns may vary between tissues and species, potentially affecting antibody binding and the observed molecular weight.

What considerations are important when validating ADRA2A antibodies for cross-species applications?

When validating ADRA2A antibodies for use across different species, researchers should consider:

• Sequence Conservation: The immunogen used to generate the antibody should be conserved across target species. For example, the Boster antibody was raised against "a synthetic peptide corresponding to a sequence in the middle region of human alpha 2a Adrenergic Receptor, identical to the related mouse and rat sequences" .

• Cross-Reactivity Assessment: Some ADRA2A antibodies are validated for multiple species (human, mouse, rat) , but using them in other species requires validation:

  Species	Validation Status	Considerations
  Human	Confirmed	Primary validation target
  Mouse	Confirmed	Commonly validated
  Rat	Confirmed	Commonly validated
  Feline	Potential but untested	Requires validation
  Other species	Variable	Sequence homology analysis needed

• Pilot Testing Protocol:

  • Western blot comparing known positive samples from validated and test species

  • Peptide competition assays to confirm specificity

  • Knockout/knockdown controls where available

As noted in a customer inquiry, the manufacturer suggested there is "a good chance of cross reactivity" with feline tissues for an antibody validated in human, mouse and rat, but recommended testing to confirm .

How can researchers distinguish between the three alpha-2 adrenergic receptor subtypes?

Distinguishing between the highly homologous alpha-2 adrenergic receptor subtypes (α2A, α2B, and α2C) requires specialized methodological approaches:

• Antibody Selection: Choose antibodies that target unique regions of each receptor subtype. For example, some antibodies target "a sequence in the middle region of human alpha 2a Adrenergic Receptor" .

• mRNA Expression Analysis: For gene expression studies, use subtype-specific primers and appropriate reference genes:

  • For human samples: GAPDH and RPS13 serve as effective reference genes

  • For animal samples: Gapdh and Rps29 are recommended

  • Use the ΔΔCt method for accurate quantification

• Knockout Controls: Utilize tissue or cells from receptor subtype-specific knockout models as negative controls.

• Pharmacological Discrimination: Use subtype-selective agonists and antagonists to distinguish functional responses in physiological experiments.

Researchers should validate their experimental approach with appropriate positive and negative controls to ensure accurate identification of specific receptor subtypes.

How do post-translational modifications affect ADRA2A detection?

Post-translational modifications (PTMs) significantly impact ADRA2A detection in experimental systems:

• Glycosylation Effects:

  • The observed molecular weight of ADRA2A (~150 kDa) is substantially higher than the calculated weight (~49 kDa)

  • Glycosylation patterns may differ between tissues and experimental conditions

  • Deglycosylation treatments may alter epitope recognition

• Experimental Strategies:

  • Use multiple antibodies targeting different epitopes

  • Consider native versus denatured conditions to assess conformational epitope recognition

  • Include controls with known PTM status

  • For critical applications, validate with deglycosylation experiments

• Data Interpretation: When analyzing ADRA2A expression, consider that changes in observed molecular weight may reflect alterations in post-translational processing rather than protein abundance.

Understanding the specific PTMs present in your experimental system is essential for accurate interpretation of ADRA2A detection results.

What experimental approaches can evaluate ADRA2A as a therapeutic target in neurodegenerative diseases?

Based on recent findings linking ADRA2A to Alzheimer's disease pathology, several experimental approaches can evaluate its therapeutic potential:

• Genetic Modulation Studies:

  • Conditional knockout models to assess temporal aspects of ADRA2A involvement

  • Region-specific knockdown to determine critical brain areas

  • Humanized mouse models expressing human ADRA2A variants

• Pharmacological Intervention Protocol:

  • Early intervention (before pathology onset) with α2AR antagonists like idazoxan

  • Dose-response relationship assessment

  • Treatment duration optimization

  • Comparison with established AD therapeutics

• Outcome Measurements:

  • Quantification of Aβ peptides (ELISA)

  • Assessment of Aβ deposition (immunohistochemistry)

  • Evaluation of neuroinflammatory markers

  • Comprehensive behavioral testing for cognitive outcomes

• Translational Considerations:

  • Blood-brain barrier penetration of candidate compounds

  • Target engagement biomarkers

  • Side effect profiles based on known ADRA2A functions

These approaches provide a framework for systematically evaluating ADRA2A as a therapeutic target in neurodegenerative diseases.